Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.04 USD | +0.17% | +0.33% | +15.65% |
Jul. 01 | Surmodics, Inc.(NasdaqGS:SRDX) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Surmodics, Inc.(NasdaqGS:SRDX) added to Russell 2000 Defensive Index | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.65% | 599M | C | ||
-7.22% | 181B | C+ | ||
-6.72% | 99.52B | C | ||
-7.50% | 65.82B | A | ||
-10.57% | 45.21B | B- | ||
+8.92% | 43.85B | B- | ||
+12.45% | 42.17B | B+ | ||
+9.65% | 28.75B | B | ||
+19.69% | 25.39B | A- | ||
-9.13% | 23.5B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRDX Stock
- Ratings Surmodics, Inc.